ImmunoGen - Antibody-Drug Conjugate


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

ImmunoGen (IMGN) is a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. Antibody-Drug Conjugate is an anti-CD37 non-Hodgkin lymphoma (NHL) candidate.

ImmunoGen (IMGN) is a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. Antibody-Drug Conjugate is an anti-CD37 non-Hodgkin lymphoma (NHL) candidate.

Company (Acquired)

Phone: 781-895-0600

Fax:

830 Winter Street

Waltham, 02451
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ImmunoGen - Antibody-Drug Conjugate $0M May 24, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ImmunoGen - Antibody-Drug Conjugate Jobs

jobs by Indeed job
						search
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)